← Browse by Condition

Medical Condition

ovarian cancer

Total Trials

54

Recruiting Now

54

Trial Phases

Phase 1, Phase 3, Phase 1, Phase 2

NCT06964009 Phase 1

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Elizabeth Stover, MD, PhD

NCT05787587 Phase 1

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

IDEAYA Biosciences

NCT04520074 Phase 3

Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)

Fudan University

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

M.D. Anderson Cancer Center

Comprehensive Outcomes for After Cancer Health

NCT06646627 Phase 1

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

Stanford University

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

United States, Austr...

NCT06395519 Phase 1, Phase 2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

858 Therapeutics, Inc.

NCT06855069 Phase 3

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Hansoh BioMedical R&D Company

NCT07216105 Phase 1

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Fate Therapeutics

NCT07030907 Phase 1

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

Outpace Bio, Inc.

NCT07225270 Phase 3

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

United States, Japan

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

United States, Austr...

University Medical Center Nijm...

NCT06819007 Phase 3

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

United States, Austr...

NCT07181720 Phase 1

CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

Chongqing Precision Biotech Co...

The Registry of Genetic Alterations of Taiwan Ovarian Cancer

National Health Research Insti...

NCT06508307 Phase 1

A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors

GONGCHU Biotechnology Co., Ltd

Feasibility of CALM in Patients With Ovarian Cancer

University Health Network, Tor...

NCT07069335 Phase 1

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

Boryung Pharmaceutical Co., Lt...

Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer

University Hospital, Grenoble

Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer

Women's Hospital School Of Med...

Patient Preferences for Precision Medicine: Determining Optimal Patient Quality of Life Using PARPi's

University of Saskatchewan

NCT04789694 Phase 3

Prehabilitation in Gynaecological Cancer Patients

Charles University, Czech Repu...

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Hospices Civils de Lyon

NCT05211557 Phase 1, Phase 2

Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer

The Affiliated Hospital of Xuz...

NCT06580002 Phase 2

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

University of California, Irvi...

Prospective Evaluation of the Role of MRI in Ovarian Masses During Pregnancy

Fondazione Policlinico Univers...

NCT07059845 Phase 2

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Australia, South Kor...

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

Emory University

NCT05316129 Phase 1

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

H. Lee Moffitt Cancer Center a...

NCT03184753 Phase 1, Phase 2

Genetically Modified T Cells Against Ovarian Cancer

Shenzhen Geno-Immune Medical I...

NCT06152731 Phase 2

HRD Tests for Ovarian cancER

Centre Francois Baclesse

FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer

Odense University Hospital

Shanghai Ovarian Cancer and Family Care Project

Shanghai First Maternity and I...

NCT03275194 Phase 2

HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy

Instituto Nacional de Cancerol...

Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses.

Belgium, Czechia, It...

Universitaire Ziekenhuizen KU ...

NCT06342986 Phase 1

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Masonic Cancer Center, Univers...

NCT05255471 Phase 3

MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.

National Cancer Institute, Nap...

NCT06321484 Phase 1

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Dana-Farber Cancer Institute

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Tongji Hospital

Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies

University Hospital Tuebingen

NCT06276491 Phase 1

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

NCT06769152 Phase 2

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

Shanghai Henlius Biotech

A Cohort Establishment Study of Total Management of Ovarian Cancer

Sichuan Cancer Hospital and Re...

NCT04585750 Phase 1, Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

United States, Austr...

PMV Pharmaceuticals, Inc

NCT06366490 Phase 1

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

PhotonPharma, Inc.

NCT06234423 Phase 1

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

United States, Austr...

OnCusp Therapeutics, Inc.

NCT04787289 Phase 2

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

British Columbia Cancer Agency

Predictive Clinical and Biological Parameters in Gynecological Cancer

Institut Paoli-Calmettes

NCT06735326 Phase 2

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

Qilu Hospital of Shandong Univ...

NCT05200260 Phase 2

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Shanghai Gynecologic Oncology ...

NCT06307249 Phase 1

Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

Lebanese University

NCT06251947 Phase 2

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Shandong University

NCT07125391 Phase 2

Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer